Home  |  About the Book  |  Table of Contents  |  Search  |  Archive  |  Order  |  Visit JCO  |  Visit ASCO.org
ASCO Educational Book; 2009
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar content in this book
Right arrow Download to citation manager
Right arrowRights & Permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Yee, C.
Right arrow Search for Related Content
PubMed
Right arrow Articles by Yee, C.

Adoptive T Cell Therapy: Stratagems and Spoils

Cassian Yee, MD

From the Fred Hutchinson Cancer Research Center, Seattle, WA

Authors’ disclosures of potential conflicts of interest are found at the end of this article.

Address reprint requests to Cassian Yee, MD, Associate Member, Fred Hutchinson Cancer Research Center, 1100 Fairview Ave. N, Rm D3-100, Seattle, WA 98109; e-mail: cyee{at}fhcrc.org

Overview: Adoptive T cell therapy represents a potent new treatment modality for patients with cancer. Potential obstacles to more effective therapy can be addressed by considering intrinsic factors, such as the phenotype of the effector T cell, and extrinsic factors, such as recipient conditioning and immune modulation. As one approach to subverting such obstacles and enhancing the efficacy of adoptive T cell therapy, we evaluate the use of antigen-specific CD4 T cells for the treatment of patients with metastatic melanoma.